Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | BCR | P11274 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.38 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.38 |
| ▸ | RAF1 | P04049 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | HTR3A | P46098 | 1/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29407694 | 1.00 | NOTUM (0.46) | NOTUMSLC22A12ABL1BCRPDE4A | |
| SCHEMBL256213 | 0.78 | NOTUM (0.47) | NOTUMABL1BCRTP53CHRNA7 | |
| SCHEMBL4086353 | 0.77 | SLC22A12 (0.42) | SLC22A12PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL21822975 | 0.77 | ADORA2A (0.41) | NOTUMSLC22A12ABL1BCRPDE4A | |
| SCHEMBL23104228 | 0.76 | NOTUM (0.46) | NOTUMABL1BCRRAF1BRAF | |
| SCHEMBL10051003 | 0.76 | PI4KA (0.52) | NOTUMABL1BCRMEN1KMT2A | |
| SCHEMBL125104 | 0.76 | NOTUM (0.46) | NOTUMABL1BCRRAF1BRAF | |
| SCHEMBL22508902 | 0.76 | SLC22A12 (0.44) | SLC22A12PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL19465328 | 0.76 | SLC22A12 (0.44) | SLC22A12PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL18572036 | 0.76 | SLC22A12 (0.48) | NOTUMSLC22A12PDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 230 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4306529-B1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS INC (US) | 2026-01-21 | — | — | EP | disclosed |
| US-12522605-B2 | FGFR inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-12390463-B2 | Dosage forms and regimens for amino acid compounds | PLIANT THERAPEUTICS, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-20250223288-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2025-07-10 | — | — | US | disclosed |
| WO-2025083426-A1 | NEW TREATMENTS FOR PAIN | SEVENLESS THERAPEUTICS LIMITED (GB) | 2025-04-24 | — | — | WO | disclosed |
| EP-4520329-A2 | TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS | Pliant Therapeutics, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| EP-4509512-A2 | AMINO ACID COMPOUNDS AND METHODS OF USE | Pliant Therapeutics, Inc. (US) | 2025-02-19 | — | — | EP | disclosed |
| EP-4499616-A1 | SPIROBICYCLIC COMPOUNDS | Acerand Therapeutics (Hong Kong) Limited (HK) | 2025-02-05 | — | — | EP | disclosed |
| US-11999758-B2 | Inhibitors of the YAP/TAZ-TEAD interaction and their use in the treatment of cancer | INVENTIVA (FR) | 2024-06-04 | — | — | US | disclosed |
| WO-2024091370-A1 | 5,6-FUSED BICYCLIC HETEROAROMATIC COMPOUNDS | ACERAND THERAPEUTICS (USA) LIMITED (US) | 2024-05-02 | — | — | WO | disclosed |
| CN-1524080-A | Phthalatyinone-piperidino-derivatives as pde4 inhibitors | ��̹��ҽҩ��˾ | 2004-08-25 | — | — | CN | disclosed |
| WO-2004056830-A1 | PYRROLOPYRIMIDINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2004-07-08 | — | — | WO | disclosed |
| US-20040067946-A1 | Phthalatyinone-piperidino-derivatives as pde4 inhibitors | TAKEDA GMBH (DE) | 2004-04-08 | — | — | US | disclosed |
| US-20040053924-A1 | 4-Substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors | SUGEN, INC. | 2004-03-18 | — | — | US | disclosed |
| WO-2004007479-A1 | 3-GUANIDINOCARBONYL-1-HETEROARYL-INDOLE DERIVATIVES, PREPARATION PROCESS, THEIR USE AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-01-22 | — | — | WO | disclosed |
| EP-1362044-A1 | PHTHALAZINONE-PIPERIDINO-DERIVATIVES AS PDE4 INHIBITORS | ALTANA Pharma AG (DE) | 2003-11-19 | — | — | EP | disclosed |
| US-6610688-B2 | For therapy of blood vessel proliferative disorders; fibrotic disorders; mesangial cell proliferative disorders; metabolic disorders; allergies; asthma; thrombosis; nervous system diseases; and cancer | SUGEN, INC. | 2003-08-26 | — | — | US | disclosed |
| US-20020183319-A1 | 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors | SUGEN, INC. | 2002-12-05 | — | — | US | disclosed |
| WO-2002064584-A1 | PHTHALAYINONE-PIPERIDINO-DERIVATIVES AS PDE4 INHIBITORS | ALTANA PHARMA AG (DE) | 2002-08-22 | — | — | WO | disclosed |
| WO-1993018035-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | ABBOTT LABORATORIES (US) | 1993-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053924-A1 | 4-Substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors | CDKN1A, CSNK1A1, CDK2 | NOTUM 4602/4885SLC22A12 3572/4885ABL1 33/4885 |
| US-20020183319-A1 | 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors | CDKN1A, CDK7, CDK2 | NOTUM 4582/4885SLC22A12 3013/4885ABL1 30/4885 |
| US-20040067946-A1 | Phthalatyinone-piperidino-derivatives as pde4 inhibitors | PDE4A, PDE4B, PDE5A | NOTUM 2311/4885SLC22A12 1649/4885ABL1 1992/4885 |
| US-12390463-B2 | Dosage forms and regimens for amino acid compounds | ITGB6, ITGA6, ITGAV | NOTUM 4360/4885SLC22A12 326/4885ABL1 955/4885 |
| US-11999758-B2 | Inhibitors of the YAP/TAZ-TEAD interaction and their use in the treatment of cancer | YAP1, TEAD2, YES1 | NOTUM 4397/4885SLC22A12 3540/4885ABL1 31/4885 |
| US-20250223288-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA6, ITGA5 | NOTUM 3976/4885SLC22A12 468/4885ABL1 697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.